Benefit of Abiraterone in metastatic prostate cancer without previous chemotherapy


Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy.
Researchers have evaluated this drug in patients who had not received previous chemotherapy.

In a double-blind study, investigators have randomly assigned 1088 patients to receive Abiraterone acetate ( 1000 mg ) plus Prednisone ( 5 mg twice daily ) or placebo plus Prednisone.

The coprimary end points were radiographic progression-free survival and overall survival.

The study was unblinded after a planned interim analysis that was performed after 43% of the expected deaths had occurred.

The median radiographic progression-free survival was 16.5 months with Abiraterone - Prednisone and 8.3 months with Prednisone alone ( hazard ratio for Abiraterone - Prednisone versus Prednisone alone, HR=0.53; P less than 0.001 ).

Over a median follow-up period of 22.2 months, overall survival was improved with Abiraterone - Prednisone ( median not reached, vs 27.2 months for Prednisone alone; HR=0.75; P=0.01 ) but did not cross the efficacy boundary.

Abiraterone - Prednisone showed superiority over Prednisone alone with respect to time to initiation of cytotoxic chemotherapy, opiate use for cancer-related pain, prostate-specific antigen progression, and decline in performance status.

Grade 3 or 4 mineralocorticoid-related adverse events and abnormalities on liver-function testing were more common with Abiraterone - Prednisone.

In conclusion, Abiraterone has improved radiographic progression-free survival, has showed a trend toward improved overall survival, and significantly has delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer. ( Xagena )

Ryan CJ et al, N Engl J Med 2013; 368:138-148

XagenaMedicine_2013



Indietro

Altri articoli

Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...


Cabozantinib ( Cabometyx ) may enhance response to immune checkpoint inhibitors ( ICIs ) by promoting an immune-permissive microenvironment and...


SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...


Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...


Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...


ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy that targets prostate-specific antigen ( PSA ), is designed to generate antigen-specific T cell...


Researchers have evaluated the use of Abiraterone acetate ( Zytiga ) ( 1,000 mg ) plus Prednisone ( 5 mg...


Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with...


STAMPEDE is a multigroup, multistage platform trial protocol investigating the efficacy of additional therapy at the time of inception of...


Over the past decade, several systemic agents as Docetaxel, Cabazitaxel, Sipuleucel-T, Abiraterone and Enzalutamide have improved overall survival ( OS...